The efficacy and safety of dendritic cells co-cultured with cytokine-induced killer cell therapy in combination with tace-predominant minimally-invasive treatment for hepatocellular carcinoma: A meta-analysis

Clinical Laboratory

Volumn 62, Issue 4, 2016, Pages 599-608

  Su, Yingying ^a   Yang, Yanming ^b   Ma, Yue ^a   Zhang, Yangyu ^a   Rai, Wenwang ^a   Yang, Guang ^a   Kou, Changgui ^a  

^a JILIN UNIVERSITY   (China)

^b THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

Cytokine induced killer cells; Dendritic cells; Hepatocellular carcinoma; Meta analysis; Treatment

Indexed keywords

ABLATION THERAPY; ARTICLE; BONE MARROW SUPPRESSION; CANCER CONTROL; CANCER IMMUNOTHERAPY; CD3+ T LYMPHOCYTE; CHEMOEMBOLIZATION; CNKI DATABASE; COCHRANE LIBRARY; CYTOKINE INDUCED KILLER CELL; DENDRITIC CELL; DENDRITIC CELL CYTOKINE INDUCED KILLER CELL IMMUNOTHERAPY; FEVER; GASTROINTESTINAL DISEASE; HUMAN; LIVER CELL CARCINOMA; MEDLINE; META ANALYSIS; MINIMALLY INVASIVE PROCEDURE; MYALGIA; OVERALL SURVIVAL; QUALITY CONTROL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); T LYMPHOCYTE SUBPOPULATION; WANFANG DATABASE; CARCINOMA, HEPATOCELLULAR; COCULTURE; IMMUNOLOGY; LIVER NEOPLASMS; MORTALITY; MULTIMODALITY CANCER THERAPY; PSYCHOLOGY; PUBLISHING;

CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; COCULTURE TECHNIQUES; COMBINED MODALITY THERAPY; CYTOKINE-INDUCED KILLER CELLS; DENDRITIC CELLS; HUMANS; LIVER NEOPLASMS; PUBLICATION BIAS;

EID: 84971425430     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: 10.7754/Clin.Lab.2015.150804     Document Type: Article

References (46)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. IntJ Cancer 2010;127(12):2893-917.
2. Word Health Organization. Cancer. WHO. November 2014. Available from: http://www.who.int/mediacentre/factsheets/ fs297/en/.
3. Kulik LM. Advancements in hepatocellular carcinoma. Curr Opin Gastroenterol 2007;23(3):268-74.
4. Imai N, Ishigami M, Ishizu Y, et al. Transarterial chemoemboli-zation for hepatocellular carcinoma: A review of techniques. World J Hepatol 2014;6(12):844-50.
5. Maleux G, van Malenstein H, Vandecaveye V, et al. Transcathe-ter chemoembolization of unresectable hepatocellular carcinoma: current knowledge and future directions. Dig Dis 2009;27(2):157-63.
6. Xu LF, Sun HL, Chen YT, et al. Large primary hepatocellular carcinoma: transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-percutaneous microwave coagulation therapy. J Gastroenterol Hepatol 2013;28(3): 456-63.
7. Huang ZM, Li W, Li S, et al. Cytokine-induced killer cells in combination with transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma patients. J Immunother 2013;36(5):287-93.
8. Xie H, Wang H, An W, et al. The efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization for primary hepatocellular carcinoma in a cohort of 487 patients. PLoS One 2014;9(2):e89081.
9. Kong QF, Jiao JB, Chen QQ, Li L, Wang DG, Lv B, . Comparative effectiveness of radiofrequency ablation with or without transarterial chemoembolization for hepatocellular carcinoma. Tumour Biol 2014 Mar;35(3):2655-9.
10. Chung YH, Han G, Yoon JH, et al. Interim analysis of START: Study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial. Int J Cancer 2013;132(10):2448-58.
11. Varga M, Valsamis A, Matia 1, et al. [Transarterial chemoembolization in hepatocellular carcinoma]. Rozhl Chir 2009 Aug;88(8): 434-8. [Article in Czech]
12. Ni JY, Sun HL, Chen YT, et al. Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma. World J Gastroenterol 2014;20(46): 17483-90.
13. Sergio A, Cristofori C, Cardin R, et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol 2008; 103(4):914-21.
14. Qu HQ, Zhou XS, Zhou XL, Wang J. Effect of DC-CIK cell on the proliferation, apoptosis and differentiation of leukemia cells. Asian Pac J Trap Med 2014;7(8):659-62.
15. Tian H, Chen G, Xu Y, Qiao M, Liu H, Wu D. Current research advance on cellular immunotherapy for leukemia-review. Chinese Association of Pathophysiology 2013 21(5):1326-30. [Article in Chinese]
16. Yang L, Ren B, Li H, et al. Enhanced antitumor effects of DC-activated ClKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients. Cancer Immunol Immunother 2013;62(1):65-73.
17. Yuanying Y, Lizhi N, Feng M, et al. Therapeutic outcomes of combining cryotherapy, chemotherapy and DC-CIK immunotherapy in the treatment of metastatic non-small cell lung cancer. Cryobiology 2013;67(2):235-40.
18. Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 1991; 174(1): 139-49.
19. Wang ZH, Qin L, Zang CY, Ma Y. Effect of IL-12 on the proliferation and cytotoxicity of CIK cells to gastric adenocarcinoma cell BGC-823. Chinese-German Journal of Clinical Oncology 2014;8:355-9.
20. Gutgemann S, Frank S, Strehl J, Schmidt-Wolf IG. Cytokine-induced killer cells are type II natural killer T cells. Ger Med Sci 2007;5:Doc07.
21. Jiang J, Wu C, Lu B. Cytokine-induced killer cells promote antitumor immunity. J Transl Med 2013;11:83.
22. Zhang Y, Zhang MJ, Jia ZS. Research advances in cellular immunotherapy for primary hepatocellular carcinoma. Chinese Journal of Clinical Hepatology. 2014;9:860-4. [Article in Chinese]
23. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012;12(4):265-77.
24. Apostolopoulos V, Pietersz GA, Tsibanis A, et al. Dendritic cell immunotherapy: clinical outcomes. Clin Transl Immunology 2014;3(7):e21.
25. Datta J, Terhune JH, Lowenfeld L, et al. Optimizing dendritic cell-based approaches for cancer immunotherapy. Yale J Biol Med 2014;87(4):491-518.
26. Dhodapkar MV, Dhodapkar KM, Palucka AK. Interactions of tumor cells with dendritic cells: balancing immunity and tolerance. Cell Death Differ 2008;15(1):39-50.
27. Ma XB, Ma C, Qiu W, Yuan HX. Study on the characteristics of culture of CIK and DC-CIK cells and their survival rate outside the incubator. Journal of Clinical and Experimental Medicine 2014;19:1587-91. [Article in Chinese]
28. Wang QJ, Wang H, Pan K, et al. Comparative study on anti-tumor immune response of autologous cytokine-induced killer (CIK) cells, dendritic cells-CIK (DC-CIK), and semi-allogeneic DC-CIK. Chin J Cancer 2010;29(7):641-8.
29. Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions. Vol 5: Wiley Online Library; 2008.
30. Cheng XZ, Peng DW, Wang MQ, Xie ZZ. Clinical efficacy of autologous dendritic cells and cytokine-induced killer cells combined with transcatheter arterial chemoembolization in the treatment of moderate-and advanced hepatocellular carcinoma. The Journal of Practical Medicine 2014;9:1401-4. [Article in Chinese]
31. Liu L. A randomized controlled study of transcatheter arterial chemoembolization combined with autologous DC-CIK cells in the treatment of advanced hepatocellular carcinoma. Second Military Medical University 2014. [Article in Chinese]
32. Wu C. Clinical research on comprehensive treatment of primary hepatocellular carcinoma. Chinese Journal of Primary Medicine and Pharmacy 2012;19(1):97-8. [Article in Chinese]
33. Xu YM, Xu DY, Zhang NZ, et al. TACE combined PMCT sequential own cancer vaccine and immunoeffector cells to treat large hepatocellular carcinoma clinical observation. Chinese Journal of Cancer Prevention and Treatment 2013;24:1928-32. [Article in Chinese]
34. Meng J, Peng DW, Wang MQ, Yu Z. Curative effect observation on autologous dendritic cells and cytokine-induced killer cells combined TACE for advanced hepatocellular carcinoma. Zhe-jiang Clinical Medical Journal 2013(8):1146-8. [Article in Chinese]
35. Wang FL. The study of hepatoma cell antigen-sensitized DC-CIK cells combined with TACE on hepatocellular carcinoma. Shandong University 2011. [Article in Chinese]
36. You ZY. Short-term clinical observation for DC-CIK immuno-therapy combined with TACE for hepatocellular carcinoma. He-bei Medical Journal 2013;35(11):1626-8. [Article in Chinese]
37. Zhang QC, Guo ZP, Guo QL, et al. DC-CIK cell therapy combined with transcatheter arterial chemoembolization and radiofre-quency ablation for treatment of small hepatocellular carcinoma. World Chinese Journal of Digestology 2014;16:2237-42. [Article in Chinese]
38. Bosetti C, Turati F, La Vecchia C. Hepatocellular carcinoma epidemiology. Best Pract Res Clin Gastroenterol 2014;28(5):753-70.
39. Miao L, Run-Ming J, Yi J. T-Bet Mediated Anti-Neoplastic Effects of Dendritic Cell-Cytokine Induced Killer Cells in vitro. Iran J Pediatr 2012;22( 1 ):43-51.
40. Chen R, Deng X, Wu H, et al. Combined immunotherapy with dendritic cells and cytokine-induced killer cells for malignant tumors: a systematic review and meta-analysis. Int Immunopharma-col 2014;22(2):451-64.
41. Wei XC, Zhai XH, Han XR, Yang DD, Wang QS. Influence of dendritic cells on biological activity of the homologous CIK cells and its anti-leukemia effect in vitro. Chinese Association of Pathophysiology 2010(18):946.
42. Pan GZ, Zhang J, Yuan QZ, Xu JB, Wang LM. Research on the Treatment of Small Hepatic Carcinoma with DC-CIK Sequential Therapy Combined with RFA and TACE. Medicine and Philosophy 2014;14:48-50. [Article in Chinese]
43. Chen BA. Killing activity in DC and CIK co-culture against he-patocarcinoma cells. Journal of Experimental Hematology 2006; 14(3):543-6. [Article in Chinese]
44. Chen G, Emens LA. Chemoimmunotherapy: reengineering tumor immunity. Cancer Immunol Immunother2013;62(2):203-16.
45. Qin Z, Blankenstein T. CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 2000; 12:677-86.
46. Rahir G, Moser M. Tumor microenvironment and lymphocyte infiltration. Cancer Immunol Immunother 2012;61 (6):751-9.